Overview

Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study

Status:
Terminated

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

The goal of this study is to evaluate the safety of melphalan and autologous PBSCT (peripheral blood stem cell transplantation - stem cells that come from your own body) in combination with bortezomib, a new FDA approved drug used to treat myeloma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Emory University

Collaborator:

Millennium Pharmaceuticals, Inc.

Treatments:

Bortezomib
Melphalan